Table 3.
BNP/NT-proBNP (pg/ml) levels at baseline and end of follow-up in the BNP-guided therapy group and symptom-guided therapy group
| BNP/NT-proBNP (pg/ml)* | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Studies that provided IPD | Studies that provided aggregate data | |||||||||||||
| Anguita [20] | Northstar [27] | Shochat [32] | Starbrite [31] | Upstep [34] | Christchurch Pilot [29] | Time-CHF [26, 33] | Berger [21] | Prima [22] | Signal-HF [25] | Battlescarred [28] | Stars-BNP [23] | Protect [30] | Guide-It [11] | |
| n = 60 | n = 407 | n = 120 | n = 130 | n = 268 | n = 69 | n = 499 | n = 278 | n = 345 | n = 252 | n = 364 | n = 220 | n = 151 | ||
| BNP guided-therapy: | ||||||||||||||
| Baseline* | 34 (7, 83) | 1884 (1385, 2955) | 1905 (1099, 4488) | 453 (221, 1135) | 601 (346, 946) | 1839 | HFrEF 3998 (2075, 7220) HFpEF 2210 (1514–4081) |
2216 (355, 9649) | 2961 (discharge) (1383, 5144) |
2661 (2.1) | 2012 (516, 10,233) | 352 (260) | 2344 | 2568 |
| End of follow-up | 8 (3, 83) | – | 1765 (476, 3966) | 413 (111, 894) | – | 1169 | – | – | 2529 | 2360 | 1610 (6 months) | 284 (180) (3 months) |
1125 | 1209 |
| Difference | 2 (−31, 28) | – | −81 (− 1273, 512) | −14 (− 461, 248) | – | − 670 | – | – | − 432 (− 1392, 297) | −301 | −402 | − 68 | 1219 | 1359 |
| % change from baseline: | 6% | – | −4% | −3% | – | −36% | – | – | −15% | − 11% | − 20% | − 19% | −52% | − 53% |
| Symptom-guided therapy: | ||||||||||||||
| Baseline* | 22 (5, 104) | 2042 (1390, 3560) | 1569 (784, 4919) | 441 (189, 981) | 609 (376, 952) | 2127 | HFrEF 4657 (2455, 7520) HFpEF 2191 (1478, 4890) |
2469 (355, 18,487) |
2936 (discharge) (1291, 5525) |
2429 (2.1) | 1996 (425, 6588) | – | 1946 | 2678 |
| End of follow-up | 39 (6, 104) |
– | 1822 (618, 4489) |
471 (236, 1180) |
– | 2102 | – | – | 2364 | 2067 | 1537 (6 months) |
– | 1844 | 1397 |
| Difference | 4 (−20, 46) | – | 73 (− 554, 1245) | 51 (− 130, 288) | – | −25 | – | – | − 572 (− 1329, 434) | − 362 | − 459 | – | 102 | 1281 |
| % change from baseline: | 18% | – | 5% | 12% | – | −1% | – | – | −19.5% | − 15% | −23% | – | −5% | − 48% |
*Median (IQR) reported for all studies except Christchurch Pilot (type of summary statistic not reported), Protect (median only reported), Signal-HF (geometric mean reported), and Stars-BNP (mean reported)
For all studies, BNP values at discharge from randomisation visit were used (assumed values at discharge reported if not stated otherwise in trial reports)
For Northstar and Upstep, BNP values at the end of follow-up were not available. For the remaining studies providing IPD, the difference between the baseline and end of follow-up was calculated as the median (IQR) change from baseline across patients. For studies providing aggregate data, the change from baseline was calculated by taking the average BNP at end of follow-up from the average BNP at baseline.
For all studies, the % change from baseline is calculated as the average difference as a percentage of the average baseline BNP